These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30680668)

  • 21. Nonhematologic toxicity of imatinib mesylate in pediatric patients with chronic myelogenous leukemia: a predominance of musculoskeletal pain.
    Heym KM; Gressett Ussery SM; Trinkman H; Philpot LM
    J Pediatr Hematol Oncol; 2015 Mar; 37(2):e111-3. PubMed ID: 25374285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic myelogenous leukemia: monitoring and predictors of a favorable response to treatment with imatinib].
    Mela Osorio MJ; Giere IA; Fernández I; Pavlovsky MA; Intile D; Pavlovsky C
    Medicina (B Aires); 2017; 77(3):161-166. PubMed ID: 28643670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
    Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
    Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
    Sharma P; Kumar L; Mohanty S; Kochupillai V
    Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
    Van Obbergh F; Knoops L; Devos T; Beguin Y; Graux C; Benghiat F; Kargar-Samani K; Bauwens D; Efira A; Dubois C; Springael C; Montfort L; Connerotte T; Capron A; Delannoy A; Wallemacq P
    Clin Biochem; 2017 May; 50(7-8):452-454. PubMed ID: 28017570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
    Campiotti L; Suter MB; Guasti L; Piazza R; Gambacorti-Passerini C; Grandi AM; Squizzato A
    Eur J Cancer; 2017 May; 77():48-56. PubMed ID: 28365527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 33. Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men.
    Belsey SL; Ireland R; Lang K; Kizilors A; Ho A; Mufti GJ; Bisquera A; De Lavallade H; Flanagan RJ
    Ther Drug Monit; 2017 Oct; 39(5):499-504. PubMed ID: 28767619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate.
    Wang XJ; Li YH
    Genet Mol Res; 2015 Jun; 14(2):6413-8. PubMed ID: 26125846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
    Mori S; Vagge E; le Coutre P; Abruzzese E; Martino B; Pungolino E; Elena C; Pierri I; Assouline S; D'Emilio A; Gozzini A; Giraldo P; Stagno F; Iurlo A; Luciani M; De Riso G; Redaelli S; Kim DW; Pirola A; Mezzatesta C; Petroccione A; Lodolo D'Oria A; Crivori P; Piazza R; Gambacorti-Passerini C
    Am J Hematol; 2015 Oct; 90(10):910-4. PubMed ID: 26178642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.
    Ojeda-Uribe M; Merieau S; Guillon M; Aujoulat O; Hinschberger O; Eisenmann JC; Kenizou D; Debliquis A; Veyradier A; Chantrel F
    J Oncol Pharm Pract; 2016 Apr; 22(2):361-70. PubMed ID: 25591869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
    Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
    Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.
    Sacha T; Góra-Tybor J; Szarejko M; Bober G; Grzybowska-Izydorczyk O; Niesiobędzka-Krężel J; Dudziński M; Wasilewska E; Myśliwiec K; Gil J; Gniot M; Pietkun I; Mędraś E; Hołojda J; Wącław J; Giannopoulos K
    Am J Hematol; 2017 Jul; 92(7):E125-E128. PubMed ID: 28376561
    [No Abstract]   [Full Text] [Related]  

  • 39. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
    Rousselot P; Prost S; Guilhot J; Roy L; Etienne G; Legros L; Charbonnier A; Coiteux V; Cony-Makhoul P; Huguet F; Cayssials E; Cayuela JM; Relouzat F; Delord M; Bruzzoni-Giovanelli H; Morisset L; Mahon FX; Guilhot F; Leboulch P;
    Cancer; 2017 May; 123(10):1791-1799. PubMed ID: 28026860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Estimated Glomerular Filtration Rate with Hemoglobin Level in Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination Survey.
    Han SY; Oh SW; Hong JW; Yi SY; Noh JH; Lee HR; Kim DJ
    PLoS One; 2016; 11(4):e0150029. PubMed ID: 27128634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.